
Andrew P. Lee
Examiner (ID: 2259, Phone: (571)270-1016 , Office: P/1621 )
| Most Active Art Unit | 1621 |
| Art Unit(s) | 1691, 1628, 1621, 1629 |
| Total Applications | 711 |
| Issued Applications | 291 |
| Pending Applications | 92 |
| Abandoned Applications | 334 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17874300
[patent_doc_number] => 11446291
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-20
[patent_title] => Methods for the treatment of abnormal involuntary movement disorders
[patent_app_type] => utility
[patent_app_number] => 17/212205
[patent_app_country] => US
[patent_app_date] => 2021-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 41777
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 207
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17212205
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/212205 | Methods for the treatment of abnormal involuntary movement disorders | Mar 24, 2021 | Issued |
Array
(
[id] => 18309616
[patent_doc_number] => 20230113516
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-13
[patent_title] => 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE FOR TREATMENT OF ACUTE LUNG INJURY
[patent_app_type] => utility
[patent_app_number] => 17/913687
[patent_app_country] => US
[patent_app_date] => 2021-03-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16552
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17913687
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/913687 | 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE FOR TREATMENT OF ACUTE LUNG INJURY | Mar 23, 2021 | Pending |
Array
(
[id] => 17095304
[patent_doc_number] => 20210283095
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-16
[patent_title] => Detection and Treatment of Viral Diseases and Cancer
[patent_app_type] => utility
[patent_app_number] => 17/249734
[patent_app_country] => US
[patent_app_date] => 2021-03-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8137
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17249734
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/249734 | Detection and Treatment of Viral Diseases and Cancer | Mar 10, 2021 | Pending |
Array
(
[id] => 18311711
[patent_doc_number] => 20230115611
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-13
[patent_title] => TREATMENT OF PAIN AND VASOCONSTRICTION
[patent_app_type] => utility
[patent_app_number] => 17/802727
[patent_app_country] => US
[patent_app_date] => 2021-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34295
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -119
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17802727
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/802727 | TREATMENT OF PAIN AND VASOCONSTRICTION | Mar 4, 2021 | Pending |
Array
(
[id] => 18404462
[patent_doc_number] => 20230165812
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-01
[patent_title] => NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE
[patent_app_type] => utility
[patent_app_number] => 17/802398
[patent_app_country] => US
[patent_app_date] => 2021-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50505
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -35
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17802398
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/802398 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | Feb 25, 2021 | Abandoned |
Array
(
[id] => 18270094
[patent_doc_number] => 20230091336
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-23
[patent_title] => CANNABINOID COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/904934
[patent_app_country] => US
[patent_app_date] => 2021-02-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24957
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17904934
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/904934 | CANNABINOID COMPOSITIONS | Feb 23, 2021 | Pending |
Array
(
[id] => 18298364
[patent_doc_number] => 20230108050
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-06
[patent_title] => CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/800639
[patent_app_country] => US
[patent_app_date] => 2021-02-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7778
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17800639
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/800639 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Feb 17, 2021 | Pending |
Array
(
[id] => 17111751
[patent_doc_number] => 20210292348
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-23
[patent_title] => ANTIVIRAL COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 17/178115
[patent_app_country] => US
[patent_app_date] => 2021-02-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 60632
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -44
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17178115
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/178115 | Antiviral compounds | Feb 16, 2021 | Issued |
Array
(
[id] => 16854882
[patent_doc_number] => 20210155627
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-27
[patent_title] => KINASE INHIBITORS AND RELATED METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/165048
[patent_app_country] => US
[patent_app_date] => 2021-02-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18389
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -45
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17165048
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/165048 | Kinase inhibitors and related methods of use | Feb 1, 2021 | Issued |
Array
(
[id] => 18225333
[patent_doc_number] => 20230064327
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-02
[patent_title] => REDUCING SIDE EFFECTS OF NMDA ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 17/792208
[patent_app_country] => US
[patent_app_date] => 2021-01-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 59015
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -174
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17792208
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/792208 | REDUCING SIDE EFFECTS OF NMDA ANTAGONISTS | Jan 21, 2021 | Pending |
Array
(
[id] => 16837808
[patent_doc_number] => 20210145820
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-20
[patent_title] => METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/154312
[patent_app_country] => US
[patent_app_date] => 2021-01-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41954
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -39
[patent_words_short_claim] => 151
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17154312
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/154312 | Methods for the treatment of abnormal involuntary movement disorders | Jan 20, 2021 | Issued |
Array
(
[id] => 19701437
[patent_doc_number] => 12195446
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-14
[patent_title] => Heteroaryl compounds and their use as therapeutic drugs
[patent_app_type] => utility
[patent_app_number] => 17/138309
[patent_app_country] => US
[patent_app_date] => 2020-12-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35688
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 555
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17138309
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/138309 | Heteroaryl compounds and their use as therapeutic drugs | Dec 29, 2020 | Issued |
Array
(
[id] => 18148343
[patent_doc_number] => 20230022200
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-26
[patent_title] => DRUG THAT PREVENTS DIALYSIS SHIFT OR RENAL DEATH
[patent_app_type] => utility
[patent_app_number] => 17/781778
[patent_app_country] => US
[patent_app_date] => 2020-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12481
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17781778
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/781778 | DRUG THAT PREVENTS DIALYSIS SHIFT OR RENAL DEATH | Dec 22, 2020 | Pending |
Array
(
[id] => 16930839
[patent_doc_number] => 20210196728
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-01
[patent_title] => METHODS OF TREATING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) DYSFUNCTION
[patent_app_type] => utility
[patent_app_number] => 17/130580
[patent_app_country] => US
[patent_app_date] => 2020-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8390
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17130580
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/130580 | Methods of treating cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction | Dec 21, 2020 | Issued |
Array
(
[id] => 16913870
[patent_doc_number] => 20210186962
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-24
[patent_title] => METHODS OF SCHIZOPHRENIA TREATMENT
[patent_app_type] => utility
[patent_app_number] => 17/127867
[patent_app_country] => US
[patent_app_date] => 2020-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6995
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17127867
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/127867 | METHODS OF SCHIZOPHRENIA TREATMENT | Dec 17, 2020 | Pending |
Array
(
[id] => 16822590
[patent_doc_number] => 20210137883
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-13
[patent_title] => ANTI-NEOPLASTIC COMPOUNDS AND METHODS TARGETING QSOX1
[patent_app_type] => utility
[patent_app_number] => 17/124242
[patent_app_country] => US
[patent_app_date] => 2020-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2458
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17124242
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/124242 | ANTI-NEOPLASTIC COMPOUNDS AND METHODS TARGETING QSOX1 | Dec 15, 2020 | Abandoned |
Array
(
[id] => 17959997
[patent_doc_number] => 20220340577
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-27
[patent_title] => GCN2 INHIBITORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/122543
[patent_app_country] => US
[patent_app_date] => 2020-12-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 210581
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17122543
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/122543 | GCN2 INHIBITORS AND USES THEREOF | Dec 14, 2020 | Pending |
Array
(
[id] => 18123535
[patent_doc_number] => 20230009145
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-12
[patent_title] => INHIBITION OF TMEM16A BY BENZBROMARONE OR NICLOSAMIDE FOR TREATING POLYCYSTIC KIDNEY DISEASE AND/OR POLYCYSTIC LIVER DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/782643
[patent_app_country] => US
[patent_app_date] => 2020-12-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8791
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17782643
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/782643 | INHIBITION OF TMEM16A BY BENZBROMARONE OR NICLOSAMIDE FOR TREATING POLYCYSTIC KIDNEY DISEASE AND/OR POLYCYSTIC LIVER DISEASE | Dec 8, 2020 | Pending |
Array
(
[id] => 17183775
[patent_doc_number] => 20210330660
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-28
[patent_title] => FORMULATIONS FOR CGRP RECEPTOR ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 17/114169
[patent_app_country] => US
[patent_app_date] => 2020-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3388
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17114169
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/114169 | FORMULATIONS FOR CGRP RECEPTOR ANTAGONISTS | Dec 6, 2020 | Abandoned |
Array
(
[id] => 17089730
[patent_doc_number] => 11117907
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-09-14
[patent_title] => Curcuminoid-inspired synthetic compounds as anti-tumor agents
[patent_app_type] => utility
[patent_app_number] => 17/112328
[patent_app_country] => US
[patent_app_date] => 2020-12-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 261
[patent_figures_cnt] => 282
[patent_no_of_words] => 40617
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 130
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17112328
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/112328 | Curcuminoid-inspired synthetic compounds as anti-tumor agents | Dec 3, 2020 | Issued |